TherapeuticsMD (TXMD) has provided an announcement. TherapeuticsMD, Inc., a healthcare company, announced its annual financial results for 2023 on March 29, 2024. The details of the results were released in
TherapeuticsMD (TXMD) has provided an announcement. TherapeuticsMD, Inc., a healthcare company, announced its annual financial results for 2023 on March 29, 2024. The details of the results were released in
קריסטן לנדון, שכיהנה בעבר כסגנית נשיא בכירה לשיווק ותקשורת ב-TherapeuticsMD, כעת תפסה את התפקיד החשוב הזה.
60 Degrees Pharmaceuticals has appointed Kristen Landon to the newly created role of Chief Commercial Officer, effective immediately. Most recently, Ms Landon served as Senior Vice President of Marketing and
Knight Therapeutics (KHTRF) announced the launch of IMVEXXY in Canada. IMVEXXY is approved for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy. VVA
Therapeuticsmd Inc (TXMD) is scheduled to report 3rd quarter earnings on 11/08/2023. Regarding Q3 estimates, Wall Street analysts expect Therapeuticsmd Inc to post earnings of -$0.15 per share. Revenue expectations